Related Experiment Video
Updated: Aug 13, 2026
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Improved Immunogenicity of the Inactivated F Genotype Mumps Vaccine against Diverse Circulating Mumps Viruses in Mice
Hyeran Won1, Ah-Ra Kim2, Gyung Tae Chung3
1Division of Vaccine Research, Center for Vaccine Research, Korea National Institute of Infectious Diseases, Cheongju 28160, Chungcheongbuk-do, Republic of Korea.
Abstract:
Mumps is an acute infectious disease caused by the mumps virus (MuV). Despite high global vaccination coverage, mumps outbreaks continue to occur, even in vaccinated populations. Therefore, we aimed to identify candidate vaccines that can induce an immunogenic response against diverse MuV genotypes with greater efficacy than the currently available options. Vaccine candidates were sourced using formalin-inactivated viral strains. The inactivated vaccines were administered to BALB/c mice (through a primer and booster dose administered after a three-week interval). We tested the neutralizing antibodies of the candidate vaccines against various MuV genotypes to determine their overall efficacy. The formalin-inactivated F genotype vaccine was found to have higher cross-neutralizing titers against genotypes F, H, and G as well as significant Th1 cytokines responses, IFN-γ, TNF-α, and IL-2 than the Jeryl Lynn (JL) vaccine. Our findings suggest that the inactivated F genotype mumps vaccine has higher immunogenicity than the JL vaccine against diverse circulating MuVs.
Insights
New mumps vaccines show promise. An inactivated F genotype mumps vaccine demonstrated superior immunogenicity and cross-neutralization against diverse mumps virus genotypes compared to the current Jeryl Lynn vaccine.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Mumps is an acute viral infection caused by the mumps virus (MuV).
- Despite widespread vaccination, mumps outbreaks persist globally, even in vaccinated individuals.
- Existing vaccines may not provide sufficient protection against diverse and circulating MuV genotypes.
Purpose of the Study:
- To identify novel mumps vaccine candidates with enhanced immunogenicity.
- To evaluate the efficacy of candidate vaccines against multiple MuV genotypes.
- To compare the immunogenic response of candidate vaccines to the current Jeryl Lynn (JL) vaccine.
Main Methods:
- Formalin-inactivated MuV strains were used to develop vaccine candidates.
- BALB/c mice received primer and booster doses of candidate vaccines.
- Neutralizing antibody titers and Th1 cytokine responses (IFN-γ, TNF-α, IL-2) were measured against various MuV genotypes.
Main Results:
- The formalin-inactivated F genotype vaccine induced higher cross-neutralizing antibody titers against MuV genotypes F, H, and G.
- This candidate vaccine also elicited significant Th1 cytokine responses (IFN-γ, TNF-α, IL-2).
- The F genotype vaccine demonstrated superior immunogenicity compared to the Jeryl Lynn vaccine.
Conclusions:
- The inactivated F genotype mumps vaccine exhibits higher immunogenicity than the JL vaccine.
- This candidate vaccine shows potential for broader protection against diverse circulating mumps virus strains.
- Further research into this candidate vaccine may lead to improved mumps prevention strategies.
